Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying

(2022) Chinmay S. Marathe et al.   Diabetes Therapy

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes

(2021) Kirsten Dahl et al.   DIABETES OBESITY & METABOLISM

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

(2021) Hitoshi Kuwata et al.   Journal of Diabetes Investigation

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

(2020) Shweta Urva et al.   DIABETES OBESITY & METABOLISM

Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution

(2020) Ryan Jalleh et al.   Nutrients

Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycemia in health and type 2 diabetes

(2019) Karen L. Jones et al.   DIABETES OBESITY & METABOLISM

Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies

(2019) Olivia M. Farr et al.   DIABETES OBESITY & METABOLISM

GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity

(2019) Hoda Kadouh et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study

(2018) V. Chedid et al.   NEUROGASTROENTEROLOGY AND MOTILITY

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

(2017) Carel W le Roux et al.   LANCET

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial

(2016) Olivia M. Farr et al.   DIABETOLOGIA

Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption

(2016) Jennifer S ten Kulve et al.   JOURNAL OF ENDOCRINOLOGY

Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy

(2015) Andres Acosta et al.   GASTROENTEROLOGY

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor

(2015) Daniel Antonio de Luis et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Questionnaire on Eating and Weight Patterns-5: An updated screening instrument for binge eating disorder

(2014) Susan Z. Yanovski et al.   INTERNATIONAL JOURNAL OF EATING DISORDERS

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

(2014) Anna Secher et al.   JOURNAL OF CLINICAL INVESTIGATION

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia

(2013) M. M. Umapathysivam et al.   DIABETES

Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes

(2013) Y. Nagai et al.   DIABETES OBESITY & METABOLISM

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

(2013) J van Can et al.   INTERNATIONAL JOURNAL OF OBESITY

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Association of TCF7L2 Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels

(2011) Maria I. Vazquez-Roque et al.   CTS-Clinical and Translational Science

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis

(2011) Priyanka Sachdeva et al.   DIGESTIVE DISEASES AND SCIENCES

TCF7L2 splice variants have distinct effects on β-cell turnover and function

(2011) Olivier Le Bacquer et al.   HUMAN MOLECULAR GENETICS

Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects: A pilot study

(2010) A. Sathananthan et al.   DIABETES CARE

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

(2009) Luan Shu et al.   HUMAN MOLECULAR GENETICS

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

(2009) Adam M. Deane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM